Medical devices works would tackle obesity new ways

Alere is working with the FDA to determine the most appropriate timing for product discontinuation and will provide guidance on transitioning patients to an alternate solution.

In December 2014, the company issued an “urgent correction” notice stating that the two devices, under certain circumstances, could display an INR that is lower than that obtained through a laboratory method. This problem could arise with blood samples from patients with any anemia accompanied by a hematocrit of less than 30%; any condition associated with elevated fibrinogen levels; or any bleeding or unusual bruising, the company said.

During the past two years, Alere worked to develop software modifications that would address the systems’ potential to deliver results that differed from lab measurements. These enhancements were submitted to the FDA at the end of 2015.

The agency notified Alere that the company’s studies did not adequately demonstrate the effectiveness of the software modifications. The FDA advised Alere to submit a proposed plan to voluntarily remove the INRatio devices from the market.

Sources: Alere, Inc.; July 11, 2016; and ASHP; July 12, 2016.

More Headlines

UCLA Team Learns Why Some Cancers Stop Responding to Immunotherapy
Discovery opens way to improved treatments
Positive Results Reported From Pivotal Phase 3 Studies of Crisaborole Ointment in Atopic Dermatitis
FDA review scheduled for January 2017
FDA Panel Recommends Approval of Etanercept (Enbrel) Biosimilar
Advisors vote unanimously for five indications
New Guidelines Back Reduced Antibiotic Use for Hospital-Acquired Pneumonia
Experts recommend seven or fewer days of therapy
Affordable Care Act helps keep spending growth at modest level, report says
Fosfomycin Demonstrates In Vitro Activity Against Bacteria Resistant to Last-Resort Antibiotic
First-in-class injectable antibiotic wins fast track designation
FDA Expands Use of Prevnar 13 Pneumonia Vaccine
Label now includes adults 18 through 48 years of age
New Diabetes Screening Recommendation Misses More Than Half of High-Risk Patients
Study evaluates USPSTF guidelines in clinical practice
FDA Advisors Recommend Approval of Adalimumab (Humira) Biosimilar
AbbVie threatens patent battle

Leave a Comment